409 Episoden
- Speed to patients and cross-border collaboration dominated conversations at London Life Sciences Week, even as investors on both sides of the Atlantic grapple with the COINS Act’s restrictions on taking equity in China-based companies. In a special live edition of the BioCentury This Week podcast, recorded at the 4th Biotech CEO & Investor Reception in London, Stephen Hansen is joined by Jackie Mulryne of Morgan Lewis, WuXi AppTec co-CEO Steve Yang, and BioCentury’s Simone Fishburn and Josh Berlin to share key takeaways from the week.
The panel discusses MHRA’s push under new CEO Lawrence Tallon to make the U.K. a hub for regulatory innovation, momentum behind non-animal methods (NAMs), and why AI-driven drug design is creating surging demand for automated wet lab capacity. They also explore why European investors see little advantage from COINS, and the split in reactions to Isomorphic Labs’ reported $5 billion raise.
View full story: https://www.biocentury.com/article/661686
#LondonLifeSciencesWeek #RegulatoryInnovation #AIDrugDiscovery #COINSAct #BiotechInvesting
0:00 Introduction
2:13 U.K. Regulatory Innovation
15:10 AI Needs Wet Labs
17:56 COINS Act and Investors
24:13 Isomorphic Valuation Debate
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text - J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III.
The analysts also assess how a growing neoantigen vaccine pipeline is testing the modality’s reach after Merck and Moderna’s Phase III win in melanoma, and the White House push that has put Heidi Overton back in play ahead of the Nov. 18 Senate HELP Committee vote on her nomination as FDA commissioner. This episode of the BioCentury This Week podcast has been brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661638
#NewCos #BiotechMA #CancerVaccines #FDA #Ophthalmology
0:01 Sponsor Message: Tigermed
1:58 J&J’s Ollin Acquisition
5:18 Blackstone’s Risk Sharing
9:13 Neoantigen Vaccine Pipeline
17:29 Overton’s FDA Nomination
24:40 Acting Commissioner Scenarios
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text - Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing legislation. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation.
The analysts also unpack full Phase III data showing pelacarsen failed across all subgroups and what it means for Lp(a) as a cardio target, highlight SITC abstracts on localizing immunotherapy within solid tumors, and discuss argenx’s $550 million upfront buyout of Unnatural Products. This episode of the BioCentury This Week podcast has been brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661519
#BiotechPolicy #FDA #DrugPricing #Cardiovascular #Immunotherapy
0:01 Sponsor Message: Tigermed
5:06 FDA Leadership After Midterms
12:41 HHS and Drug Pricing
17:34 Pelacarsen Readout at AHA
22:31 SITC Abstract Highlights
25:57 argenx’s Peptide Deal
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text - Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from the event.
The panel assesses what the COINS Act could mean for U.S. investment in China biotech and how investors may adapt, how China’s 30-day IND review and new investigator-initiated trial rules are reshaping clinical strategy, and what dealmaking reveals about the country’s growing first-in-class pipeline. They also preview BioCentury’s East-West Summit in Seoul, March 15-17.
View full story: https://www.biocentury.com/article/661483
#ChinaBiotech #COINSAct #ClinicalTrials #FirstInClass #BiotechPartnering
0:00 Live from China Healthcare Summit
5:20 China's Role in Biotech R&D
9:06 What COINS Could Mean for U.S. Investors
11:37 Faster IND Reviews and New IIT Rules
17:27 First-Order Innovation in China
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text - A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss why new targets alone may not be enough to overcome resistance.
Turning to policy, the analysts examine Representative Jake Auchincloss’ Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us biobank. They also discuss how U.S. investors are reacting to Treasury's proposed COINS Act rule, including a workaround that pays Chinese licensors on exit instead of with equity, and former FDA Commissioner Janet Woodcock's proposals to make individualized rare disease therapies commercially viable.
View full story: https://www.biocentury.com/article/661405
#ADCs #ClinicalTrials #BiotechPolicy #ChinaBiotech #RareDisease
0:00 Introduction
1:34 ESMO First-in-Human Analysis
10:26 Faster Clinical Trials Act
19:27 COINS Act and NewCos
28:19 Woodcock's Rare Disease Proposals
31:53 Biotech IPO Debuts
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text
Weitere Biowissenschaften Podcasts
Trending Biowissenschaften Podcasts
Über BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Podcast-WebsiteHöre BioCentury This Week, پادکست آذرخش مکری - azarakhsh mokri und viele andere Podcasts aus aller Welt mit der radio.de-App

Hol dir die kostenlose radio.de App
- Sender und Podcasts favorisieren
- Streamen via Wifi oder Bluetooth
- Unterstützt Carplay & Android Auto
- viele weitere App Funktionen
BioCentury This Week: Zugehörige Podcasts
















